Cordis’ addition of the Chocolate PTA balloon catheter complements and expands its existing portfolio of high-performance lower extremity products, including the S.M.A.R.T. line of self-expanding stents, percutaneous transluminal angioplasty balloon catheters, and chronic total occlusion devices.

Cordis worldwide president Celine Martin noted the company is is pleased to have the opportunity to partner with TriReme Medical on this exciting and highly differentiated technology.

"As a leader in endovascular technologies, this agreement represents our continuing commitment to identifying optimal solutions for patients suffering from peripheral artery disease," Martin added.

The Chocolate PTA balloon catheter, approved in the US in December 2011, is a unique PTA balloon that is designed to allow for atraumatic dilatation in treating peripheral artery disease (PAD).

The Chocolate PTA balloon catheter is indicated for balloon dilatation of lesions in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal and renal arteries. Its unique nitinol constraining structure creates uniform ‘pillows’ that make contact with the vessel and "valleys" that allow for plaque modification and are designed to relieve stress upon inflation.

Data from the Chocolate BAR registry, a prospective, core lab-adjudicated registry conducted at 33 US clinical centers, was presented at the 2014 Leipzig Interventional Course (LINC) earlier this month by Dr. Das who is an investigator of the study.

Results on the first 350 patients enrolled in the registry treated with the Chocolate PTA balloon catheter demonstrated high rates of treatment success and limb preservation. Patients enrolled in the registry had advanced atherosclerotic disease in their legs and included patients at high risk of amputation (Rutherford 5 and 6, total occlusions, long and calcified lesions).

The Chocolate PTA balloon catheter expands Cordis’ high-performance lower extremity portfolio and represents the company’s continuing commitment to advancing its endovascular leadership. Through the company’s innovation, research and development, Cordis partners with clinicians worldwide to treat millions of patients who suffer from peripheral artery disease.